Cisplatin is one of the most potent and widely used chemotherapeutic agent in the treatment of several solid tumors, despite the high toxicity and the frequent relapse of patients due to the onset of drug resistance.

Resistance to chemotherapeutic agents, either intrinsic or acquired, is currently one of the major problems in oncology. Thus, understanding the biology of chemoresistance is fundamental in order to overcome this challenge and to improve the survival rate of patients. Studies over the last 30 decades have underlined how resistance is a multifactorial phenomenon not yet completely understood. Recently, tumor metabolism has gained a lot of interest in the context of chemoresistance; accumulating evidence suggests that the rearrangements of the principal metabolic pathways within cells, contributes to the sensitivity of tumor to the drug treatment.

In this review, the principal metabolic alterations associated with cisplatin resistance are highlighted. Improving the knowledge of the influence of metabolism on cisplatin response is fundamental to identify new possible metabolic targets useful for combinatory treatments, in order to overcome cisplatin resistance.

顺铂是治疗几种实体瘤的最有效和广泛使用的化学治疗剂之一，尽管由于耐药性的发作，其毒性高且患者经常复发。

对内源性或后天性化学治疗剂的抗性目前是肿瘤学中的主要问题之一。因此，了解化学抗药性是克服这一挑战并提高患者存活率的基础。过去30年的研究强调，抗性是一种尚未完全理解的多因素现象。最近，在化学抗性的背景下，肿瘤代谢引起了人们的极大兴趣。越来越多的证据表明，细胞内主要代谢途径的重排有助于肿瘤对药物治疗的敏感性。

在这篇综述中，强调了与顺铂耐药性相关的主要代谢改变。增进对新陈代谢对顺铂反应影响的认识，对于确定新的可能用于联合治疗的新的代谢靶标，以克服顺铂耐药性至关重要。